Obesity and Cardio-vascular Disorders: Review

##plugins.themes.bootstrap3.article.sidebar##

PDF (Українська)
Published: Jul 30, 2020
DOI: https://doi.org/10.30841/2307-5112.3.2020.211860
Keywords:
body mass іndex, obesity, «obesity paradox», cardio-vascular disease, heart failure, metabolіcally healthy obesity, obesity cardіomіopathy,

##plugins.themes.bootstrap3.article.main##

В. В. Горбачова
State Scientific Institution «Center for Innovative Medical Technologies of the National Academy of Science of Ukraine», Ukraine
https://orcid.org/0000-0002-2514-3468
О. І. Плегуца
State Scientific Institution «Center for Innovative Medical Technologies of the National Academy of Science of Ukraine», Ukraine
https://orcid.org/0000-0002-5695-6111

Abstract

The article reviews an association between increased body mass index and obesity and cardio vascular abnormalities. It is proven, that patients with excess body weight and obesity develop hemodynamic, structural, functional heart and blood vessels disorders, which increase the risk of hypertension, atrial fibrillation, coronary heart disease, chronic heart failure, stroke and increase the risk of death from cardiovascular diseases. Currently, there is an ongoing discussion in the global medical community regarding the existence of such definitions as «metabolically healthy phenotype of obesity», «obesity paradox», «obesity cardiomyopathy». According to modern concepts «metabolically healthy obesity» is considered only as a transition state between a normal metabolically healthy state and metabolically unhealthy obesity. The «obesity paradox» states that patients with chronic heart failure and excess body weight or obesity have a better survival prognosis compared to patients with normal or low body mass index. Therefore, weight loss is not recommended in such patients. However, there are controversial questions regarding the reason for the difference in «obesity paradox» survival. Also, the question remains unclear whether isolated obesity can lead to «obesity cardiomyopathy» due to the lipids accumulation in cardiomyocytes, inflammation, neurohormonal and cellular disorders. It is important to understand the above conditions in order to have a clear idea if there is a need for a therapeutic management. An indisputable tactic is to prevent weight gain and obesity in order to prevent cardiovascular and metabolic diseases. With existing obesity, different treatment options are offered, one of the effective treatment option is a bariatric surgery treatment.

##plugins.themes.bootstrap3.article.details##

How to Cite
Горбачова, В. В., & Плегуца, О. І. (2020). Obesity and Cardio-vascular Disorders: Review. Family Medicine, (3), 47–51. https://doi.org/10.30841/2307-5112.3.2020.211860
Issue
No. 3 (2020)
Section
For practicing physicians
Copyright (c) 2020 В. В. Горбачова, О. І. Плегуца

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.

Author Biographies

В. В. Горбачова, State Scientific Institution «Center for Innovative Medical Technologies of the National Academy of Science of Ukraine»

Vira V. Gorbachova,

Head of Diagnostic Department

О. І. Плегуца, State Scientific Institution «Center for Innovative Medical Technologies of the National Academy of Science of Ukraine»

Oleksandr I. Plegutsa,

Department of Endocrine and Metabolic Surgery

References

Aimo A, Januzzi JL Jr, Vergaro G, et al. (2019). Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. Eur J Prev Cardiol. 26:1751–59.

Alexander JK. (1985). The cardiomyopathy of obesity. Progress in cardiovascular diseases. 27:325–34.

Aron-Wisnewsky J, Prifti E, Belda E, Ichou F, Kayser BD et al. (2019). Major microbiota dysbiosis in severe obesity: fate after bariatric surgery. Gut. 68:70–82.

Banerjee S. (2007). Myocardial metabolism and cardiac performance in obesity and insulin resistance. Current Cardiology Reports. 9:143–9.

Bell JA, Hamer M, Sabia S, Singh-Manoux A, Batty GD, Kivimaki M. (2015). The natural course of healthy obesity over 20 years. J Am Coll Cardiol. 65:101–102.

Bozkurt B. (2016). Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation. 134:e579–e646.

Carbone S, Lavie CJ, Arena R. (2017). Obesity and heart failure: focus on the obesity paradox. Mayo Clin Proc. 92:266–79.

Drosatos K, Schulze PC. (2013). Cardiac lipotoxicity: molecular pathways and therapeutic implications. Current Heart Failure Reports. 10:109–121.

Ebong IA. (2014). Mechanisms of heart failure in obesity. Obesity Research and Clinical Practice. 8:e540–e548.

Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, et al. (2011). Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index) National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 countryyears and 9.1 million participants. Lancet. 377:557–67.

GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. (2017). Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 377:13–27.

Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, et al. (2001). The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 38:789–95.

http://www.euro.who.int/en/healthtopics/noncommunicable-diseases/obesity/data-and-statistics (30 May 2016).

Hubert HB, Feinleib M, McNamara PM, Castelli WP. (1983). Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 67:968–77.

Ingelsson E. (2005). Insulin resistance and risk of congestive heart failure. Jama. 294:334–341.

Jamaly S, Carlsson L, Peltonen M, Jacobsen P, Karason K. (2019). Surgical obesity treatment and the risk of heart failure. Eur Heart J. 40:2131–38.

Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305–13.

Kenchaiah S, Gaziano JM, Vasan RS. Impact of obesity on the risk of heart failure and survival after the onset of heart failure. Medical Clinics of North America 2004;88:1273–94.

Lassale C, Tzoulaki I, Moons KGM, et al. (2018). Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis. Eur Heart J. 39:397–406.

Lavie CJ, Alpert MA, Arena R, et al. (2013). Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail. 1:93–102.

Lavie CJ, Sharma A, Alpert MA, De Schutter A, Lopez-Jimenez F, et al. (2016). Update on obesity and obesity paradox in heart failure. Prog Cardiovasc Dis. 58:393–400.

McDowell K, Petrie MC, Raihan NA, Logue J. (2018). Effects of intentional weight loss in patients with obesity and heart failure: a systematic review. Obes Rev. 19:1189–1204.

Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. (2016). The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 35:1–23.

Nagarajan V, Kohan L, Holland E, Keeley EC, Mazimba S. (2016). Obesity paradox in heart failure: a heavy matter. ESC Heart Failure. 3: 227–34.

Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, et al. (2008). Body mass index and mortality in heart failure: a meta-analysis. Am Heart J. 156:13–22.

Packer M. (2018). Leptin–aldosterone–neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation. 137:1614–31.

Padwal R, McAlister FA, McMurray JJV, Cowie MR, Rich M, et al. (2014). Meta-Analysis Global Group In Chronic Heart Failure (MAGGIC). The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. Int J Obes Relat Metab Disord. 38:1110–4.

Pinto YM. (2016). Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. European Heart Journal. 37:1850–58.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, et al. (2016). ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 37:2129–2200.

Schwarzl M, Ojeda F, Zeller T, Seiffert M, Becher PM, et al. (2016). Risk factors for heart failure are associated with alterations of the LV end-diastolic pressure–volume relationship in non-heart failure individuals: data from a large-scale, population-based cohort. Eur Heart J. 37:1807–14.

Strohl KP, Strobel RJ, Parisi RA. (2004). Obesity and pulmonary function. In: Bray GA, Bouchard C, James WP, eds. Handbook of obesity: etilogy and pathophysiology. 2nd ed. New York, Marcel Dekker: 725–39.

Timoh T. (2012). A perspective on obesity cardiomyopathy. Obesity Research and Clinical Practice. 6:e181–e188.

Tromp J, Westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ et al. (2018). Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 72:1081–1090.

Velho S, Paccaud F, Waeber G, Vollenweider P, Marques-Vidal P. (2010). Metabolically healthy obesity: different prevalences using different criteria. Eur J Clin Nutr. 64:1043–51.

Vest AR, Chan M, Deswal A, Givertz MM, Lekavich C, et al. (2019). Nutrition, obesity, and cachexia in patients with heart failure: a consensus statement from the Heart Failure Society of America Scientific Statements Committee. J Card Fail. 25:380–400.

Wannamethee SG, Shaper AG, Whincup PH, et al. (2011). Obesity and risk of incident heart failure in older men with and without pre-existing coronary heart disease: does leptin have a role? J Am Coll Cardiol. 58:1870–77.

World Health Organization Technical Report 894. Obesity: preventing and managing the global epidemic. Geneva: World Health Organization, 2000.